Exhibit (a)(1)(B)
Letter of Transmittal
To Tender Shares of Common Stock
of
THESEUS PHARMACEUTICALS, INC.
a Delaware corporation
at
A Cash Amount per Share between $3.90 and $4.05, Consisting of a Base Price Per Share of $3.90 and
an Additional Price Per Share of up to $0.15, Plus One Non-Transferable Contractual Contingent Value Right for Each Share (“CVR”), Which Represents the Right to Receive One or More Potential Cash Payments, Contingent upon Receipt of Proceeds from Any Disposition of CVR Products Within 180 Days of the Closing Date and the Realization of Certain Specified Potential Cost Savings
Within 180 Days of the Closing Date, as Described in the CVR Agreement
Pursuant to the Offer to Purchase
Dated January 9, 2024
by
CONCENTRA MERGER SUB II, INC.,
a wholly owned subsidiary of
CONCENTRA BIOSCIENCES, LLC
TANG CAPITAL PARTNERS, LP
TANG CAPITAL MANAGEMENT, LLC
THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE ONE MINUTE AFTER
11:59 P.M., EASTERN TIME, ON FEBRUARY 7, 2024 (THE “EXPIRATION DATE”),
UNLESS THE OFFER IS EXTENDED OR EARLIER TERMINATED.
The Depositary and Paying Agent for the Offer Is:
Broadridge Corporate Issuer Solutions, LLC
If delivering by hand, express mail, courier or other expedited service: | | | If delivering by mail: |
| | ||
Broadridge Corporate Issuer Solutions, LLC Attention: BCIS IWS 51 Mercedes Way Edgewood, NY 11717 | | | Broadridge Corporate Issuer Solutions, LLC Attention: BCIS Re-Organization Dept. P.O. Box 1317 Brentwood, NY 11717-0718 |